Bunkerhill AVC vs Tempus ECG-AF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Bunkerhill Health
VS
by Tempus AI, Inc.

AI Verdict

Tool A (Bunkerhill AVC) specializes in the automated detection and quantification of various calcifications (aortic, coronary, mitral) and bone density from chest CT scans. Conversely, Tool B (Tempus ECG-AF) focuses on identifying the risk of new-onset atrial fibrillation in patients aged 65 or older by analyzing 12-lead ECG recordings. While both are FDA-cleared cardiology AI tools, their distinct input modalities and specific clinical targets mean they address different diagnostic needs within cardiovascular health.

Choose Bunkerhill AVC if…

Choose Bunkerhill AVC if your health system seeks to opportunistically screen for multiple cardiovascular calcifications (aortic, coronary, mitral) and bone density from existing chest CT scans. This tool is ideal for integrating generative AI-powered insights directly into EHR workflows to automate detection and quantification, enhancing comprehensive patient risk assessment across cardiology and radiology departments.

View Bunkerhill AVC →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your practice focuses on proactively identifying patients aged 65 or older at increased risk of developing new-onset atrial fibrillation within the next 12 months. This AI-based algorithm is specifically designed to analyze 12-lead ECG recordings for this purpose, supporting earlier identification and follow-up in a defined at-risk population.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Bunkerhill AVC Tempus ECG-AF
Pricing Unknown Contact vendor
Deployment Unknown Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available Yes AI-estimated Yes AI-estimated
FDA Status Cleared AI-estimated Yes AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Bunkerhill AVC

Tool A, Bunkerhill AVC, explicitly highlights 'customizable AI agents for diverse workflows' and 'Natural language processing for patient record interaction (Carebricks Chat)'. These features suggest a more interactive and adaptable user experience, allowing for dynamic engagement with clinical data beyond just receiving results. Tool B focuses on compatibility with specific ECG machines, which is important for integration but less indicative of advanced user interaction.

Clinical Value

Bunkerhill AVC

While both tools are FDA-cleared and address significant clinical needs, Tool A (Bunkerhill AVC) offers a broader suite of opportunistic findings from a single CT scan, including aortic, coronary, and mitral calcification, as well as bone density assessment. Its 'Generative AI for clinical reasoning and action' also implies a wider application beyond mere detection, potentially enhancing overall clinical decision-making. Tool B focuses on a specific predictive risk from ECGs for a defined patient population.

Pricing & Value

Tempus ECG-AF

Tool B (Tempus ECG-AF) provides clear financial transparency by explicitly mentioning CMS reimbursement availability with specific CPT codes (0764T and 0765T) and a Medicare rate of $128.90. This offers a direct pathway for value realization and adoption. In contrast, Tool A only states 'contact for pricing,' providing no immediate insight into cost-effectiveness or potential revenue generation.

Enterprise Readiness

Tie

Both Tool A and Tool B demonstrate strong enterprise readiness, as both are FDA-cleared, HIPAA compliant, and offer Business Associate Agreements (BAA). Both also integrate with existing healthcare facility systems and EHRs, indicating a comparable level of preparedness for deployment in clinical environments.

Innovation

Bunkerhill AVC

Tool A's emphasis on 'Generative AI for clinical reasoning and action,' 'customizable AI agents,' and 'Natural language processing for patient record interaction (Carebricks Chat)' suggests a more advanced and flexible application of AI. This approach moves beyond specific diagnostic detection towards broader clinical intelligence and workflow customization, representing a higher degree of innovation in its underlying AI capabilities.

Support & Docs

Tempus ECG-AF

Tempus (Tool B) explicitly mentions a support email ([email protected]) and the option to 'Talk with a live representative in real time' for its AI Apps Suite, which includes ECG-AF. It also references a 'Document Library' for resources. Bunkerhill Health's information focuses more on the platform's capabilities to automate tasks and reduce workload, rather than providing explicit details on direct support channels or documentation availability.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Bunkerhill AVC Tempus ECG-AF
Product Name Bunkerhill AVC Tempus ECG-AF
Company BunkerHill Health Tempus AI, Inc.
Primary Function Aids in the early detection and quantification of aortic valve calcification from chest CTs. Analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.
Input Data Type Chest CTs 12-lead ECG recordings
Target Condition(s) Aortic valve calcification (AVC), coronary artery calcification (iCAC, Contrast CAC), mitral annular calcification (MAC), opportunistic bone density assessment (BMD). Atrial fibrillation/flutter (AF)
Target Patient Population Not specified Patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.

Videos

Demos, reviews, and walkthroughs featuring Bunkerhill AVC and Tempus ECG-AF.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Bunkerhill AVC is designed for the early detection and quantification of aortic valve calcification, coronary artery calcification, mitral annular calcification, and opportunistic bone density assessment from chest CTs. Tempus ECG-AF analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.
Bunkerhill AVC analyzes chest CT scans, including both non-contrast and contrast-enhanced studies. Tempus ECG-AF analyzes 12-lead ECG recordings.
Bunkerhill AVC is intended for adult patients aged 40 years and above for aortic valve calcification detection. Tempus ECG-AF is intended for patients 65 years of age or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.
Bunkerhill AVC integrates with full Electronic Health Records (EHRs) and clinical archives within health systems. Tempus ECG-AF integrates as a software solution into healthcare facility systems and is compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems.
Bunkerhill AVC has a new national billing code and associated payment under the Hospital Outpatient Prospective Payment System (OPPS) for algorithmic analysis of coronary artery calcium and aortic valve calcium on chest CT scans, effective April 1, 2026. Tempus ECG-AF has CMS reimbursement available (CPT 0764T and CPT 0765T to APC 5734, Medicare rate of $128.90, effective January 1, 2025).
Bunkerhill AVC provides automated detection and quantification of aortic valve calcification, coronary artery calcification, mitral annular calcification, and opportunistic bone density assessment. Tempus ECG-AF detects signs associated with new onset Atrial Fibrillation (AF) within 12 months.
Bunkerhill AVC is primarily designed for Cardiology and Radiology. Tempus ECG-AF is primarily designed for Cardiology, Geriatrics, and Internal Medicine.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.